EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte Studie

Impact of systemic resveratrol on non-surgical periodontal treatment of smokers: A 12-month randomized clinical trial

Vanessa Haguihara Lucchesi, Ana Paula Oliveira Giorgetti, Mônica Grazieli Corrêa, Vanessa G A Pecorari, Bruno Braga Benatti, Howard C Tenenbaum, Fabiano Ribeiro Cirano, Suzana Peres Pimentel, Márcio Zafallon Casati

Clinical Oral Investigations · 30.08.2025 · 29 (9)

DOI: 10.1007/s00784-025-06517-9 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Clinical Oral Investigations, online erschienen am 30.08.2025. Verfasst von Vanessa Haguihara Lucchesi und 8 weiteren Autor:innen. Beteiligte Einrichtung: Dental Research Division, Scholl of Dentistry, Universidade Paulista (UNIP), São Paulo, São Paulo, Brazil. Hauptthemen laut MEDLINE: Resveratrol, Periodontitis, Smoking. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 71 Literaturangaben. Gefördert von: The National Council for Scientific and Technological Development.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVE: Smoking patients demonstrate an elevated risk of periodontitis development and respond poorly to periodontal therapy as compared to nonsmokers, and resveratrol (RSV) demonstrated a positive effect in the reduction of periodontitis progression in both animal and clinical trials. However, to the authors' knowledge, no clinical study has assessed the impact of resveratrol under smoking conditions. Thus, this trial aimed to evaluate the effect of systemic administration (SA) of RSV adjunct to full-mouth ultrasonic debridement (FMUD) of periodontitis smoking patients (PSP). MATERIALS AND METHODS: Thirty-eight individuals were randomly assigned to two groups:Placebo ( n = 19) -FMUD and placebo for 180 days; RSV ( n = 19) FMUD and RSV (500 mg/day) for 180 days. Clinical and immunoinflammatory outcomes were assessed at baseline, 3-, 6-, and 12-months post-therapy, and microbiological outcomes were evaluated at baseline, 3-, 6- months post-therapy. RESULTS: RSV appeared to induce lower PD [2.96 (0.41) - 3 months; 2.85 (0.40) - 6 months; 2.80 (0.35)- 12 months], CAL [4.02 (0.90) - 3 months; 4.04 (0.81) - 6 months; 3.87 (0.78) - 12 months], and PMG [2.20 (0.56) - 3 months; 2.28 (1.14) - 6 months; 2.32 (3.27) - 12 months] readings as compared to Placebo [PD: 3.22 (0.51) - 3 months; 3.07 (0.42) - 6 months; 3.02 (0.42) - 12 months; CAL: 4.43 (0.99) - 3 months; 4.24 ((0.89) - 6 months; 4.39 (0.93) - 12 months; PMG: 2.50 (0.50) - 3 months; 2.53 (0.45) - 6 months; 2.67 (0.46) - 12 months] throughout the time (p < 0.05). The concentration of Aggregatibacter actinomycetemcomitans (Aa) was significantly higher in moderate [2.29 (1.10); 1.61 (1.02) for PL and RSV, respectively] and deep PD [2.39 (1.14); 1.73 (0.90) for PL and RSV respectively] at 3 months for the Placebo group (p < 0.05). Additionally, Aa levels were lower at 6 months in the deep sites for the RSV group (p < 0.05) [1.77 (0.94); 2.23 (1.08) for PL and RSV, respectively]. Immunoinflammatory analysis showed lower levels of IL-1β at 3-month periods in deep sites in the RSV group [92.6 ± 84.2; 35.36 (52.92) for PL and RSV, respectively] and lower concentrations of IL-6 in the RSV group at 3 and 12 months in both moderate [8.11 (9.50); 4.67 (4.20) - 3 months for PL and RSV, respectively; 8.01 ± 3.52; 5.33 (4.14) - 12 months for PL and RSV, respectively]; and deep sites [4.69 (3.06); 3.57 (3.73) - 3 months for PL and RSV, respectively]; 3.50 (2.67); 2.10 (0.89) - 12 months for PL and RSV, respectively] (p < 0.05). CONCLUSION: In conclusion, systemic administration of RSV improves clinical results and modulates IL-1β at 3 months, IL-6 at 3- and 6- months, in deep sites of smoking patients when associated with FMUD. TRIAL REGISTRATION: Rebec identifier https//ensaiosclinicos.gov.br/rg/RBR3gt65c.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ResveratrolPeriodontitisSmokingHumansMaleFemaleMiddle AgedTreatment OutcomeAdultUltrasonic TherapyPeriodontal DebridementSmokersDouble-Blind Method

Stichwörter der Autor:innen

Periodontal debridement.PeriodontitisResveratrolSmoking

Substanzen

Resveratrol

Autor:innen und Institutionen

  • Dental Research Division, Scholl of Dentistry, Universidade Paulista (UNIP), São Paulo, São Paulo, Brazil.
  • Dental Research Division, Biostatistcs Department, Scholl of Dentistry, Universidade Paulista (UNIP), São Paulo, São Paulo, Brazil.
  • School of Dentistry, Federal University of Maranhão, São Luís, MA, Brazil.
  • Department of Periodontology, Faculty of Dentistry and Laboratory Medicine and Pathobiology, Faculty of Medicine, University of Toronto, Toronto, ON, Canada.
  • School of Dental Medicine, Department of Periodontics, Tel Aviv, University, Tel Aviv, Israel.
  • Depto de Odontologia, Universidade Paulista - UNIP, Av. Dr. Bacelar, 1212, 4o andar, Vila Clementino, São Paulo, 04026-002, SP, Brazil. mzcasati@gmail.com.

Förderung

  • The National Council for Scientific and Technological Development

Zitieren

APA

Lucchesi, V. H., Giorgetti, A. P. O., Corrêa, M. G., Pecorari, V. G. A., Benatti, B. B., Tenenbaum, H. C., Cirano, F. R., Pimentel, S. P., & Casati, M. Z. (2025). Impact of systemic resveratrol on non-surgical periodontal treatment of smokers: A 12-month randomized clinical trial. Clinical Oral Investigations, 29(9). https://doi.org/10.1007/s00784-025-06517-9

Vancouver

Lucchesi VH, Giorgetti APO, Corrêa MG, Pecorari VGA, Benatti BB, Tenenbaum HC, et al. Impact of systemic resveratrol on non-surgical periodontal treatment of smokers: A 12-month randomized clinical trial. Clinical Oral Investigations. 2025;29(9). doi:10.1007/s00784-025-06517-9

BibTeX
@article{Lucchesi2025,
  author = {Lucchesi, Vanessa Haguihara and Giorgetti, Ana Paula Oliveira and Corrêa, Mônica Grazieli and Pecorari, Vanessa G A and Benatti, Bruno Braga and Tenenbaum, Howard C and Cirano, Fabiano Ribeiro and Pimentel, Suzana Peres and Casati, Márcio Zafallon},
  title = {Impact of systemic resveratrol on non-surgical periodontal treatment of smokers: A 12-month randomized clinical trial},
  journal = {Clinical Oral Investigations},
  year = {2025},
  volume = {29},
  number = {9},
  doi = {10.1007/s00784-025-06517-9}
}
Kostenlos starten →